Lindsey Shapiro, PhD,  science writer—

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Half of AAV Patients in Study Develop Poor Long-Term Outcomes

Half of patients with ANCA-associated vasculitis (AAV) developed a poor long-term outcome — kidney disease, cancer or death — in the years after their diagnosis, according to a recent study in China. Impaired kidney filtration, low blood potassium, older age, and kidney or heart involvement at diagnosis were among…

Altered Blood Vessel Repair Process ID’d in GPA Remission Patients

The function of endothelial colony-forming cells (ECFCs) is impaired in people with granulomatosis with polyangiitis (GPA) — a type of ANCA-associated vasculitis (AAV) — who are in disease remission, according to a recent study. Impairments in ECFCs’ ability to repair damaged blood vessels — their normal role — even…

Immune Checkpoint Molecules Linked to Risk of Relapse in AAV

Blood levels of molecules called soluble immune checkpoints (sICPs) may serve as biomarkers of relapse risk in people with ANCA-associated vasculitis (AAV), a study found. Patients with lower levels of these molecules were more likely to relapse after being in remission following treatment with rituximab, but were less likely…

Blocking Immune Molecule IL-21 May Be Target as MPO-AAV Therapy

Levels of the immune signaling molecule interleukin-21 (IL-21) and the cells that produce the protein were elevated in the blood of people with ANCA-associated vasculitis (AAV) with myeloperoxidase (MPO) antibodies, a study found. IL-21 levels also were linked to higher MPO levels and disease activity, suggesting its direct involvement in…